Orchestra BioMed Holdings, Inc. (OBIO) stock intrinsic value fair value estimate & owner earnings analysis

Orchestra BioMed Holdings (OBIO) is a clinical-stage medical device company built around two licensed technologies: AVIM Therapy, a pacemaker add-on for uncontrolled high blood pressure, and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), for re-narrowed coronary arteries after stenting. Neither has FDA approval yet, and the company earns essentially no product revenue today. AVIM Therapy is exclusively licensed to Medtronic, the world's largest pacemaker maker, under an agreement that pays Orchestra between $500 and $1,600 per device for at least 12 years if the therapy is approved and sold. A completed pilot study already showed a statistically significant blood-pressure reduction of about 11 mmHg, and Medtronic has continued investing in the partnership, most recently agreeing in 2025 to integrate the therapy into its next-generation leadless pacemaker. The pivotal trial supporting FDA approval is completing patient enrollment around mid-2026, but no pivotal results exist yet, and approval, if it comes, is likely several years away. Virtue SAB is earlier and less certain: its prior commercial partner, Terumo, walked away from its distribution agreement in October 2025 (retaining only a right of first refusal, not a commitment), and a new, separate coronary trial only began enrolling patients that same month. Because there is no approved, selling product, the company has lost money every year since going public, and the dollar loss has grown each year (from roughly $34 million in 2022 to roughly $61 million in 2024), funded almost entirely by issuing new shares — the share count has more than quadrupled over that period. A one-time accounting item inflated reported 2025 results: the last of a legacy $30 million payment Terumo made back in 2019 was booked as revenue only because the relationship ended, not because of new business; we excluded that year when setting the recurring loss level. Cash burn has accelerated further in 2026 as both pivotal trials run at once and as Orchestra reimburses Medtronic for integration costs under the 2025 amendment. As of mid-2026 the company held about $110 million in cash and investments, funded partly by a $15 million loan from Hercules Capital (2028 maturity), an up-to-$35 million royalty-financing deal with Ligand Pharmaceuticals (repaid only out of future product royalties, so it costs shareholders nothing if no product ever reaches market), and a new $20 million convertible loan from Medtronic carrying an above-market 11% rate. Net of these claims, per-share cash today is modest and shrinking. Our bear case assumes the pivotal trial or FDA review disappoints and neither product reaches market in a reasonable time; the company keeps diluting shareholders to fund itself before eventually winding down or selling remaining assets, leaving a small residual value. Our base case assumes the pivotal data confirms the pilot's benefit, FDA approval follows around 2029, and Medtronic rolls the therapy out gradually — meaningful royalty income arrives, but only after several more years of dilution, and a portion of every dollar is owed to Ligand. Our bull case assumes a strong trial readout, a faster Medtronic rollout across its dominant pacemaker franchise, and a new commercial partner secured for Virtue SAB, making the company a genuine royalty earner within the decade. Given this is close to an all-or-nothing outcome with real financing claims ahead of shareholders, the margin-of-safety price assumes the worst case is a real possibility, leaving substantial room for the trial data to disappoint.